GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Vigabatrin

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Sabril / Vigabatrin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Sabril - product and source limitations

Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Sabril - product and source limitations

Official source

Sabril - labeled renal guidance

Renal action and limits

Vigabatrin (Sabril), oral tablet
Creatinine clearance (CrCl), mL/min

Action or finding
For adults and children age 2 years or older, reduce the usual dose by 25% at CrCl above 50 through 80, by 50% above 30 through 50, and by 75% above 10 through 30 mL/min.
Limits and monitoring
Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 40, posted Dec 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source Sabril | GlobalRPh RX passage All evidence
Product / population
Vigabatrin (Sabril), oral tablet
Renal measure
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 40, posted Dec 17, 2025
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2.4 Patients with Renal Impairment / 8.6 Renal Impairment

For adults and children age 2 years or older, reduce the usual dose by 25% at CrCl above 50 through 80, by 50% above 30 through 50, and by 75% above 10 through 30 mL/min. Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements.

Source revision: DailyMed SPL version 40, posted Dec 17, 2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5d389d2-d0e1-4395-a2a2-b552808e7f98

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Sabril - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 40, posted Dec 17, 2025

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Sabril - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Sabril - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Sabril - product and source limitations

Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements.

How to use this: Apply only to the stated formulation, indication and renal population.

Sabril - labeled renal guidanceSabril - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeSabril - labeled renal guidanceSabril - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/vigabatrin/

Indication and usual adult dosing

Original SABRIL indication: adjunctive refractory complex partial seizures after inadequate response to several alternatives, when benefit outweighs vision-loss risk; not first-line treatment.

500 mg tablets orally twice daily with or without food. Start 500 mg twice daily (1 g/day); increase total daily dose by 500 mg weekly according to response. Recommended adult dose 1.5 g twice daily (3 g/day). Six g/day had no additional benefit and more adverse events.

Withdraw gradually. The source adult trials tapered the total daily dose by 1 g at weekly intervals until discontinuation.

GRPH-vigabatrin-01 · Source section: Indication and usual adult dosingRenal section finder

Renal Dosing

Primarily renal elimination. Original CrCl bands: above 50-80 mL/min, reduce dose 25%; above 30-50, reduce 50%; above 10 to under 30, reduce 75%. The wording leaves exactly 30 unassigned.

Cockcroft-Gault estimate: (140 - age) x weight in kg / (72 x serum creatinine in mg/dL), multiplied by 0.85 for females.

GRPH-vigabatrin-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Effect of dialysis on clearance was not adequately studied.

GRPH-vigabatrin-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Sabril - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Vigabatrin (Sabril), oral tablet

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 40, posted Dec 17, 2025
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.4 Patients with Renal Impairment / 8.6 Renal Impairment

For adults and children age 2 years or older, reduce the usual dose by 25% at CrCl above 50 through 80, by 50% above 30 through 50, and by 75% above 10 through 30 mL/min. Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements.

RDM74-sabril-official-1 · Source locator: Renal guidance: 2.4 Patients with Renal Impairment / 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5d389d2-d0e1-4395-a2a2-b552808e7f98
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 40, posted Dec 17, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
9b2368f4c67577b6b903f205e98cae5af0853930b37d054e117805b55e13afc1
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Sabril - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Vigabatrin (Sabril), oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

For adults and children age 2 years or older, reduce the usual dose by 25% at CrCl above 50 through 80, by 50% above 30 through 50, and by 75% above 10 through 30 mL/min.

RDM74-sabril-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/sabril-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
cab87c7184e61ea6b4bf54938a7f86d74dc35df6391b8732588d5f6c550d0378

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/vigabatrin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
ef72f9c9088e7b17e9650b01208acd6f04cc3efbb7b7538ceb1d1658d96d439d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top